Today: 7 February 2026
Subscribe

Energy stocks face a Monday test after OPEC+ holds output, oil near $61

Energy stocks face a Monday test after OPEC+ holds output, oil near $61

NEW YORK, January 4, 2026, 13:55 ET — Market closed OPEC+ kept oil output unchanged on Sunday after a brief meeting, reaffirming a plan by eight key members to pause production increases — meaning no additional barrels — through March, the group said. It will meet again on Feb. 1, as the oil market digests political shocks from Yemen to Venezuela. “Right now, oil markets are being driven less by supply–demand fundamentals and more by political uncertainty,” said Jorge Leon, head of geopolitical analysis at Rystad Energy. Reuters That backdrop matters for energy stocks because the sector entered 2026 with
4 January 2026
···
Nvidia stock heads into CES week after insider sale filing puts NVDA back in focus

Nvidia stock heads into CES week after insider sale filing puts NVDA back in focus

NEW YORK, Jan 4, 2026, 13:49 ET — Market closed Nvidia (NVDA.O) shares closed up 1.2% on Friday after a company officer filed notice of a planned share sale, with investors also bracing for CEO Jensen Huang’s headline slot at CES in Las Vegas. SEC The filing matters because it lands at the start of a year when the market is looking for fresh proof that the artificial-intelligence spending boom is still translating into revenue and margins, not just bigger capital budgets. It also comes as tech valuations remain sensitive to interest-rate expectations, after Federal Reserve officials warned this weekend
4 January 2026
··
Indore water crisis widens to nerve-disorder fears as Mangaluru clears chargers for 100 e-buses

Indore water crisis widens to nerve-disorder fears as Mangaluru clears chargers for 100 e-buses

NEW DELHI, Jan 4, 2026, 13:54 ET A drinking-water contamination outbreak in Indore has taken a fresh turn after doctors flagged symptoms consistent with Guillain-Barre syndrome, a rare disorder in which the immune system attacks nerves, in a 67-year-old patient from the city’s Bhagirathpura area, NDTV reported. Officials have confirmed six deaths in the diarrhoea outbreak, while local residents have claimed the toll is 16. Ndtv The suspected neurological complication matters because it could widen the public-health response from short-term gastroenteritis to longer-term disability, raising pressure on authorities to explain what went wrong with the city’s water supply and how
4 January 2026
Vertiv stock jumps on Barclays upgrade, $200 target; U.S. jobs report looms for AI-linked industrials

Vertiv stock jumps on Barclays upgrade, $200 target; U.S. jobs report looms for AI-linked industrials

NEW YORK, Jan 4, 2026, 14:01 ET — Market closed Vertiv Holdings shares jumped 8.4% on Friday after Barclays upgraded the industrial stock to overweight and lifted its price target to $200. “The recent selloff in the shares creates an attractive entry point,” Barclays analyst Julian Mitchell wrote. TipRanks The upgrade matters now because the market has started 2026 trying to separate durable “picks-and-shovels” beneficiaries of artificial intelligence from the frothier corners of the trade. Vertiv sells the power and cooling gear that data centers need to run denser, heatier AI workloads. That theme helped value-tilted sectors including industrials hold
4 January 2026
···
Dyne Therapeutics stock drops 5% into 2026 — FDA filing timeline and next earnings date in focus

Dyne Therapeutics stock drops 5% into 2026 — FDA filing timeline and next earnings date in focus

NEW YORK, January 4, 2026, 13:49 ET — Market closed Dyne Therapeutics shares closed down 5.5% on Friday at $18.50, ending the first U.S. trading session of 2026 on a softer note. About 2.65 million shares changed hands. The pullback matters because 2026 is shaping up as a timing-driven year for the clinical-stage biotech, with investors focused on whether its lead Duchenne muscular dystrophy program can reach regulators on schedule and on what that path costs. Dyne said in December its Phase 1/2 DELIVER trial met its main biomarker goal, lifting dystrophin — a muscle protein missing in Duchenne —
4 January 2026
···
Consumer Cyclical Stocks wobble into Monday as Tesla drags XLY and jobs report looms

Consumer Cyclical Stocks wobble into Monday as Tesla drags XLY and jobs report looms

NEW YORK, January 4, 2026, 13:55 ET — Market closed The Consumer Discretionary Select Sector SPDR ETF, a widely followed proxy for consumer cyclical stocks, ended Friday down 0.9% at $118.35 as Tesla and Amazon fell. Consumer cyclical stocks—companies tied to discretionary spending on items like cars and home furnishings—often swing with shifts in jobs and interest-rate expectations. That sensitivity matters heading into the first full trading week of 2026, with key U.S. data set to reset the market’s view on growth and rate cuts. Reuters “The market is looking for direction,” Matthew Maley, chief market strategist at Miller Tabak,
4 January 2026
······
Berkshire Hathaway stock: OxyChem deal closes as investors size up the Abel era

Berkshire Hathaway stock: OxyChem deal closes as investors size up the Abel era

NEW YORK, Jan 4, 2026, 14:01 ET — Market closed Berkshire Hathaway said on Friday it completed its acquisition of Occidental Petroleum’s chemicals business OxyChem, a $9.7 billion all-cash deal that adds a major plastics and industrial chemicals producer to the conglomerate. Business Wire The timing matters. Berkshire is entering 2026 with investors focused on how the company puts money to work after a long stretch of sitting on cash and trimming some big equity positions, even as markets remain richly valued. It also lands as Berkshire shifts from a Warren Buffett-led story to one where capital allocation and succession
4 January 2026
·
Freshworks stock drops 5% to start 2026 — what matters before Monday’s open (FRSH)

Freshworks stock drops 5% to start 2026 — what matters before Monday’s open (FRSH)

NEW YORK, Jan 4, 2026, 13:47 ET — Market closed Freshworks Inc shares closed down 5.3% at $11.60 on Friday and ticked up 0.5% in after-hours trading, when U.S. stocks change hands electronically outside the regular 9:30 a.m. to 4 p.m. session. The software maker is valued at about $3.3 billion and is near the lower end of its 52-week range. MarketBeat The move matters because investors opened 2026 with a cautious eye on interest rates, a key input for valuing growth stocks that rely on future cash flows. U.S. Treasury yields pushed higher on Friday, with the 10-year yield
4 January 2026
···
Asana stock slides 5% to start 2026 — downgrade and key dates that could move ASAN next

Asana stock slides 5% to start 2026 — downgrade and key dates that could move ASAN next

NEW YORK, January 4, 2026, 13:41 ET — Market closed. Asana, Inc. (ASAN) shares fell about 5.4% on Friday to $12.96, finishing near the session low after trading between $12.92 and $13.84. Research outlet Wall Street Zen downgraded the stock to “hold” from “buy” on Saturday, MarketBeat reported. MarketBeat The slide leaves Asana heading into Monday’s reopen with investors focused on whether 2026 brings more rate relief or a longer pause. Philadelphia Fed President Anna Paulson said on Saturday that another U.S. rate cut could take a while, after the Fed lowered rates by 75 basis points in 2025, Reuters
4 January 2026
···
Cloud computing stocks slide into 2026 as yields rise — what CLOU ETF investors watch next

Cloud computing stocks slide into 2026 as yields rise — what CLOU ETF investors watch next

NEW YORK, January 4, 2026, 13:43 ET — Market closed The Global X Cloud Computing ETF fell 2.34% on Friday to $22.09, ending the first U.S. trading session of 2026 on the back foot as investors trimmed rate-sensitive cloud software exposure. Global X ETFs The timing matters because cloud stocks have become a crowded way to express bets on corporate digital spending and AI-linked demand, but they tend to wobble when bond yields rise. On Friday, U.S. stocks finished mixed with the Nasdaq edging lower as megacap tech weighed, while Treasury yields climbed. Reuters Policy expectations are also moving. Philadelphia
4 January 2026
·······
ZoomInfo stock slides 5.5% — key levels and the next dates investors are watching

ZoomInfo stock slides 5.5% — key levels and the next dates investors are watching

NEW YORK, Jan 4, 2026, 13:41 ET — Market closed ZoomInfo Technologies Inc (GTM.O) shares closed down 5.5% on Friday at $9.61, setting the software and data company up for a cautious start to the new week when U.S. markets reopen on Monday. The selloff pushed the stock below its 50-day and 200-day moving averages — common charting gauges that smooth daily price swings — at about $10.23 and $10.45, MarketBeat data showed. The same dataset put ZoomInfo’s consensus analyst rating at “Hold” with an average price target of roughly $11.79, leaving shares about 18% below that level after Friday’s
4 January 2026
·
Nike stock (NKE) heads into Monday after Friday dip as insiders and jobs data loom

Nike stock (NKE) heads into Monday after Friday dip as insiders and jobs data loom

NEW YORK, Jan 4, 2026, 12:45 ET — Market closed Nike, Inc. shares slipped in the first trading session of 2026, closing Friday down 0.67% at $63.28. The stock traded between $62.55 and $64.13, with about 22.2 million shares changing hands. StockAnalysis That matters now because Nike is trying to stabilize a multi-quarter reset while investors look for early proof the turnaround is working. In its last quarterly report, Nike said gross margin fell 300 basis points — three percentage points — to 40.6%, and Nike Direct revenue declined as digital sales dropped 14%. Macro risk is back in focus
4 January 2026
····
1 … 948 949 950 951 952 … 2,714

Stock Market Today

Pfizer stock price rises into weekend as FDA priority review, TrumpRx discounts grab focus

Pfizer stock price rises into weekend as FDA priority review, TrumpRx discounts grab focus

7 February 2026
New York, February 7, 2026, 05:48 EST — Market closed Pfizer Inc (PFE) shares ended Friday up 2.8% at $27.22, after trading between $26.52 and $27.37. About 50.7 million shares changed hands. (Yahoo Finance) The stock’s late-week lift comes with a key regulatory clock running: the FDA granted priority review for Pfizer’s supplemental filing to broaden use of its hemophilia drug Hympavzi, with a target decision deadline in the second quarter. Priority review shortens the agency’s standard review timeline by four months. “There is a significant medical need for younger patients with hemophilia and for those who have developed inhibitors,”
Go toTop